Melanoma is a form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.
Ludwig Cancer Research scientists have developed a method to significantly improve the preclinical evaluation of chimeric antigen-receptor (CAR) T cell therapies.
Adoptive transfer of T-cells can extend survival and, at times, treat patients with advanced solid tumors.
A groundbreaking new type of cancer immunotherapy developed at the Icahn School of Medicine at Mount Sinai trains the innate immune system to help it eliminate tumor cells through the use of nanobiologics, tiny materials bioengineered from natural molecules that are paired with a therapeutic component, according to a study published in Cell in October.
Until recently, it was believed that the innate immune system, the body's first line of defense, lacked the ability to remember pathogens like the adaptive immune system.
Immunotherapies, such as checkpoint inhibitor drugs, have made worlds of difference for the treatment of cancer. Most clinicians and scientists understand these drugs to act on what's known as the adaptive immune system, the T cells and B cells that respond to specific threats to the body.
To identify new potential therapeutic targets for SARS-CoV-2, a team of scientists at the New York Genome Center, New York University, and the Icahn School of Medicine at Mount Sinai, performed a genome-scale, loss-of-function CRISPR screen to systematically knockout all genes in the human genome.
Research led by Queen Mary University of London has revealed novel insights into the mechanisms employed by melanoma cells to form tumours at secondary sites around the body.
The evolution of the refined human immune system has turned into an effective defense system against several diseases, including cancer.
An Edith Cowan University (ECU) study has revealed that a key blood marker of cancer could be used to select the most effective treatment for melanoma.
The development of cancer is a highly complicated process, involving multiple genes and signaling pathways that become upregulated or downregulated throughout different stages of tumor growth and spread. Two of the most commonly altered genes in cancer are p53 and AKT.
Scientists have discovered that a drug that may make some melanoma tumors perceptible to the immune system, enabling them to be better targeted.
Researchers at the UCLA Jonsson Comprehensive Cancer Center have found that a drug that activates the body's natural defenses by behaving like a virus may also make certain stealthy melanoma tumors visible to the immune system, allowing them to be better targeted by immunotherapy.
Neoantigens, tiny markers that arise from cancer mutations, flag cells as cancerous and could be the key to unlocking a new generation of immunotherapies.
Risk for melanoma, the most deadly skin cancer, can be estimated long before detection of any suspicious moles, according to a UC San Francisco scientist who led a new study to detect DNA mutations in individual skin cells.
New research shows how the gut microbiome communicates with an oral drug in prostate cancer patients.
Scientists have shown that blocking the construction of nuclear pores complexes shrank aggressive tumors in mice while leaving healthy cells unharmed.
Researchers at the University of Bern have discovered a mechanism in the body’s own immune system which is responsible for the maturation and activation of immune cells.
In laboratory studies, Johns Hopkins Kimmel Cancer Center and Johns Hopkins University researchers observed a key step in how cancer cells may spread from a primary tumor to a distant site within the body, a process known as metastasis.
The immune protein STING has long been noted for helping protect against viruses and tumors by signaling a well-known immune molecule. Now, UT Southwestern scientists have revealed that STING also activates a separate pathway, one that directly kills tumor-fighting immune cells.
A molecule recently discovered by scientists can trigger a natural immune-boosting protein, known as STING (short for STimulator of INterferon Genes).